Validierung der Behavioral Activation for Depression Scale bei Personen mit Substanzgebrauchsstörungen (BADS-SUD)
Psychometrische Validierung der Behavioral Activation for Depression Scale (BADS) in einer klinischen Stichprobe von Personen mit Substanzgebrauchsstörungen
This cross-sectional observational study evaluates the psychometric properties, structural validity, item response characteristics, and concurrent criterion validity of the Behavioral Activation for Depression Scale (BADS) in adults receiving clinical treatment for substance use disorders (SUD). The study examines the scale's dimensional structure, reliability, and association with environmental reward (Environmental Reward Observation Scale, EROS) in a primary clinical cohort of 289 participants. Concurrent and discriminant validity analyses with additional clinical measures (assessing borderline symptom severity, impulsivity, anxiety, and anger expression) were evaluated in a verified sequential subcohort of 59 participants with fully confirmed individual-level linkage across multi-scale administration sheets. This retrospective study record documents the completed psychometric evaluation conducted within a specialized residential therapeutic community.
Studienübersicht
Status
Detaillierte Beschreibung
This study employs a cross-sectional observational design to evaluate the psychometric properties and dimensional structure of the Spanish version of the Behavioral Activation for Depression Scale (BADS) in individuals receiving residential or intensive clinical treatment for substance use disorders. The completed validation protocol comprises two complementary analytic components:
-
Primary Cohort Analyses (N = 289):
Analyses of internal structure, categorical confirmatory factor analysis (using WLSMV estimation on polychoric correlations), exploratory structural equation modeling (ESEM), bifactor modeling, item response theory (Samejima's Graded Response Model), and internal consistency reliability were conducted in a primary clinical sample of 289 adult patients. Item completeness reached 99.7% across the 25 BADS items (288 complete records, 1 record with six items omitted). Concurrent criterion validity with perceived environmental reward was examined across this entire cohort using the Environmental Reward Observation Scale (EROS).
-
Secondary Multi-Scale Clinical Analyses (Verified n = 59):
Concurrent and discriminant relationships with external clinical constructs-including borderline symptom severity (BSL-23), impulsivity (BIS-11), generalized anxiety (GAD-7), and anger expression (STAXI-2)-were evaluated. Although 155 multi-scale records were captured during clinical testing and earlier study drafts described an analytic target of 127 participants, retrospective quality control revealed an unindexed row offset in spreadsheet transcriptions beginning at record 60. To maintain strict scientific integrity and avoid mispairing, concurrent multi-battery analyses are reported exclusively on the initial sequential subcohort of 59 participants whose individual identity, sex, age, and questionnaire administration sequence are verified at 100%. Remaining captured records remain designated as pending verification against institutional physical charts.
This record reflects the retrospective documentation and post-completion reconciliation of the completed study protocol.
Studientyp
Einschreibung (Tatsächlich)
Kontakte und Standorte
Studienorte
-
-
Jalisco
-
Ajijic, Jalisco, Mexiko, 45920
- Comunidad Terapéutica Under The Tree
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
The study population consists of adults receiving residential treatment for substance use disorders in a therapeutic community setting. Participants represent a clinically relevant population characterized by difficulties in mood regulation, behavioral activation, emotional dysregulation, and related psychological symptoms commonly associated with substance use disorders.
Beschreibung
Inclusion Criteria:
- Adults aged 18 to 68 years.
- Primary clinical diagnosis of Substance Use Disorder (evaluated in accordance with DSM-5 criteria) currently receiving residential or intensive clinical treatment in a therapeutic community setting.
- Literacy and fluency in Spanish sufficient to complete self-report instruments.
- Provision of voluntary written informed consent.
- Completion of the Behavioral Activation for Depression Scale (BADS).
Exclusion Criteria:
- Severe cognitive impairment, active psychosis, or acute neurological conditions precluding accurate self-reporting.
- Active substance intoxication or acute withdrawal symptoms at the time of testing that interfere with questionnaire completion.
- Substantial missing data preventing psychometric modeling (participants with at least 75% item completion on the primary instrument were retained for categorical estimation under pairwise/FIML algorithms).
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: CASE_ONLY
- Zeitperspektiven: CROSS_SECTIONAL
Kohorten und Interventionen
Gruppe / Kohorte |
|---|
|
Individuals With Substance Use Disorders
Single clinical group composed of adults receiving treatment for substance use disorders who completed the Behavioral Activation for Depression Scale (BADS) and additional self-report measures as part of a cross-sectional observational study. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Psychometric Validity of the Behavioral Activation for Depression Scale (BADS)
Zeitfenster: Baseline (single cross-sectional assessment).
|
Psychometric properties of the Behavioral Activation for Depression Scale (BADS), including internal structure (confirmatory factor analysis), internal consistency reliability (Cronbach's alpha and/or omega), and construct validity (convergent and discriminant validity), assessed using self-report data collected at a single time point in individuals with substance use disorders. Subscale scores will also be examined, with higher scores reflecting greater expression of the respective behavioral domains. |
Baseline (single cross-sectional assessment).
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Convergent and Discriminant Validity of the Behavioral Activation for Depression Scale With the Borderline Symptom List-23
Zeitfenster: Single cross-sectional assessment conducted at the time of psychological evaluation during residential treatment.
|
Convergent and discriminant validity of the Behavioral Activation for Depression Scale will be examined through its association with scores on the Borderline Symptom List-23, a self-report measure of borderline symptom severity and behavioral dysregulation. The Borderline Symptom List-23 provides a mean total score ranging from 0 to 4, with higher scores indicating greater severity of borderline symptomatology. Associations will be analyzed using continuous scores to evaluate the extent to which behavioral activation and avoidance patterns measured by the Behavioral Activation for Depression Scale relate to clinical severity and emotional dysregulation in individuals with substance use disorders. The Borderline Symptom List-23 is a 23-item self-report scale scored on a 5-point Likert-type format (0 to 4), producing a mean total score ranging from 0 to 4. Higher scores indicate greater severity of borderline symptomatology and emotional dysregulation. |
Single cross-sectional assessment conducted at the time of psychological evaluation during residential treatment.
|
|
Convergent Validity of the Behavioral Activation for Depression Scale With the Environmental Reward Observation Scale
Zeitfenster: Single cross-sectional assessment conducted at the time of psychological evaluation during residential treatment.
|
Convergent validity of the Behavioral Activation for Depression Scale (BADS) will be evaluated through its association with the Environmental Reward Observation Scale (EROS), a self-report measure assessing perceived availability and frequency of environmental positive reinforcement. The EROS consists of 10 items scored on a 4-point Likert-type scale (1 = strongly disagree to 4 = strongly agree), yielding total scores ranging from 10 to 40, with higher scores indicating greater perceived availability of environmental positive reinforcement. Correlations between BADS subscale and total scores and EROS scores will be analyzed as continuous variables across the primary clinical cohort (N = 289) to examine the theoretical correspondence between behavioral activation processes and perceived environmental reinforcement in a residential substance use treatment setting. |
Single cross-sectional assessment conducted at the time of psychological evaluation during residential treatment.
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Lauro Gutiérrez Castro, Under The Tree Therapeutic Community
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- BADS-SUD-VALID-01
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .